| Autor: |
McDonald, A., Verburgh, E., Gotti, M., Pinto, A., Zaucha, J., Ivanov, V., Melnichenko, V., Mocikova, H., Ozcan, M., Patti, C., Farias, J., Goncalves, I., Kuchkova, O., Mayer, J., Saydam, G., Tomassetti, S., Pathiraja, K., Ryland, K., Chakraborty, S., Jurczak, W. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p575-577, 3p |
| Abstrakt: |
B Conclusions: b With approximately 9 mo of follow-up, pembro 400 mg Q6W had robust antitumor activity in pts with R/R cHL and R/R PMBCL, with ORR similar to that with pembro 200 mg Q3W. B Introduction: b Pembrolizumab (pembro) was originally approved by the FDA for the treatment of R/R cHL and R/R PMBCL at 200 mg every 3 weeks (Q3W). Treatment-related AEs occurred in 24 pts (40%) with R/R cHL and 2 (33.3%) with R/R PMBCL; grade >=3 treatment-related AEs occurred in 3 pts (5%) and 1 pt (16.7%), respectively. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text